Skip Navigation

'There are more medicines and diagnostic tools, but still no clean water'

Malaria interventions unlikely to improve health unless causes of dysfunctional health systems are tackled, an ACT Consortium researcher told members of the UK Parliament.

What is the ACT Consortium?

Our research aims to improve the access and targeting, and to assess the quality and safety of artemisinin-based combination therapy (ACT), the WHO recommended first-line treatment for malaria.

News from our Partners

The U.S. President’s Malaria Initiative (PMI) is developing a PMI Strategy for 2015–2020 and seeking external comment by 30 September.

Multimedia section

Watch videos, browse a prezi and listen to podcasts with ACT Consortium investigators talking about their studies on the access, targeting, quality and safety of ACT drugs.

Malaria research publications

Browse through more than 70 journal articles published by ACT Consortium investigators on the access, targeting, safety and quality of antimalarials.

View all ACT Consortium news

The ACT Consortium is an international research collaboration formed in November 2007 to answer key questions on malaria drug delivery in Africa and Asia.  

Our goal is to develop and evaluate delivery mechanisms to improve ACT access, targeting, safety and quality. 

The ACT Consortium is funded by the Bill & Melinda Gates Foundation and has partners throughout Africa, Asia, Europe and the United States.  It is coordinated through the London School of Hygiene & Tropical Medicine.